Everest Organics Ltd to Consider September Results on Nov 12

Everest Organics Ltd will consider unaudited standalone financial results for the quarter and half year ended September 30, 2026, at its board meeting on November 12, 2026, with trading restricted until 48 hours after the results are declared. The meeting will also consider the Statutory Auditors' Limited Review Report.

What will Everest Organics Ltd consider at its November 12 meeting?

Everest Organics Ltd has informed BSE that its Board of Directors will meet on Thursday, November 12, 2026, to consider and approve unaudited standalone financial results for the September 2026 quarter and the first half of FY27. The agenda includes the Limited Review Report to be issued by the company's statutory auditors.

The announcement was made on November 9 under the listing regulations. Results for the September quarter will provide the next formal update on the pharmaceutical and biotechnology company's operating and financial performance after its June-quarter disclosure.

The company has not disclosed the September-quarter financial outcome in the board-meeting intimation. The meeting is intended to consider the results, so investors will need to await the board's decision and the subsequent exchange filing for the reported figures and management disclosures.

Why is Everest Organics Ltd's trading window closed?

Everest Organics Ltd's trading window has remained closed from October 1, 2026, and will reopen 48 hours after the declaration of the unaudited September-quarter results. The restriction applies in connection with the impending release of financial information that may be price-sensitive.

A trading-window closure is a standard governance measure for listed companies around financial-result announcements. It is designed to restrict trading by designated persons while unpublished price-sensitive information may be available internally. The company has specified the reopening condition as 48 hours after the result declaration rather than a fixed calendar date.

For public shareholders, the key implication is that the window closure does not itself indicate the direction of the results. It is a compliance step linked to the board meeting and the planned financial disclosure.

What was Everest Organics Ltd's latest reported financial performance?

Everest Organics Ltd reported standalone revenue of ₹48.85 crore in Q1 FY27 and net profit of ₹1.11 crore. Revenue was broadly unchanged from ₹48.91 crore in Q4 FY26, while net profit declined from ₹2.63 crore in the preceding quarter.

On a year-on-year basis, Q1 FY27 revenue was 10.1% lower, while net profit was 20.8% lower, according to the disclosed quarterly data. Expenditure was ₹47.32 crore, and the operating profit margin was 8.93%, compared with 13.74% in Q4 FY26.

The following table summarises the available standalone financial data and the upcoming disclosure event.

How does the September-quarter filing matter to investors?

The September-quarter filing will show whether Everest Organics Ltd's revenue and profitability changed after the June quarter, when revenue was nearly flat sequentially but profit and operating margin declined from Q4 FY26. It will also provide first-half FY27 figures, allowing investors to assess the company's performance over two quarters rather than a single reporting period.

The company is classified in the Pharmaceuticals & Biotechnology industry and has a micro-cap market capitalisation. For companies of this size, periodic result disclosures can be particularly important because they provide a formal basis for tracking changes in sales, expenditure, margins and profitability.

The statutory auditors' Limited Review Report is also part of the agenda. Such a review accompanies unaudited quarterly results and is relevant to investors assessing the financial statements placed before the board. The BSE filing after the meeting should set out the approved numbers and the related audit-review information.

What recent corporate developments provide context?

Everest Organics Ltd held its 33rd annual general meeting on September 30, 2026. Shareholders adopted the audited FY26 financial statements, and the company appointed three independent directors, according to the available company update. Whole-Time Director Venkata Satya Subbarao Pachigolla was also re-appointed.

The latest board-meeting notice follows that annual governance cycle and focuses on the first-half FY27 financial update. The September 2026 quarterly announcement will be the first scheduled results consideration after the annual general meeting.

The available shareholding data showed promoter ownership at 59.6% through Q1 FY27. That figure provides context on ownership concentration, although the board-meeting notice itself does not indicate any change in shareholding, capital structure or business operations.

Conclusion

Everest Organics Ltd's November 12 board meeting is a scheduled financial-results event covering unaudited standalone performance for the quarter and half year ended September 30, 2026. The company has maintained its trading-window closure from October 1 until 48 hours after the disclosure, in line with the stated compliance process.

Investors will next watch for the board-approved September-quarter revenue, profit, margin and expenditure figures, together with the Statutory Auditors' Limited Review Report. The exchange filing after the meeting will clarify how the company performed after reporting Q1 FY27 revenue of ₹48.85 crore and net profit of ₹1.11 crore.